Brugada syndrome is an autosomal dominant genetic disorder associated with an increased risk of sudden cardiac death, as well as ventricular tachyarrhythmias.The defective cardiac sodium channels result in usual electrocardiographic findings of a coved-type ST elevation in precordial leads V1 to V3. The majority of patients have uncomplicated courses with anesthesia, surgery, and invasive procedures. However there is risk of worsening ST elevation and ventricular arrhythmias due to perioperative medications, surgical insult, electrolyte abnormalities, fever, autonomic nervous system tone, as well as other perturbations. Given the increasing numbers of patients with inherited conduction disorders presenting for non-cardiac surgery that are at risk of sudden cardiac death, safe anesthetic management depends upon a detailed knowledge of these conditions. 
The type 1 ECG pattern is coved-type, with the ST elevation being more prominent (≥2 mm or 0.2 mV) and slopes down (convex upward or concave downward) with the T-wave being inverted [ Figure 1 ]. The type 2 ECG pattern is referred to as the "saddle back" configuration, with a less prominent ST elevation (<2 mm) followed by sloping toward the baseline before an upright T-wave, which may be DEFINITION OF BRUGADA SYNDROME AND BRUGADA PATTERN ELECTROCARDIOGRAM Brugada syndrome is an autosomal dominant genetic disorder associated with an increased risk of sudden cardiac death (SCD), as well as ventricular tachyarrhythmias. In certain patient populations, the syndrome is referred to as sudden unexpected death syndrome or sudden unexpected nocturnal death syndrome. [1] Since its initial description in 1992, patients with Brugada syndrome have no structural heart disease by echocardiography, but have distinctive electrocardiographic findings. [2] The electrocardiogram (ECG) shows a coved-type ST-segment elevation in two or more anteroseptal precordial (V1-V3) leads [ Figure 1 ]. Infrequently, the inferior leads (limb leads II, III, and aVF) may show similar findings. The ST elevation can be variable depending on other factors such as electrolyte abnormalities, autonomic tone, and fever. [3] The configuration of the ST elevation helps differentiate between Brugada pattern type 1 and type 2 (previously, three separate configurations were described; however, recent consensus statements define biphasic [ Figure 1 ]. Differentiation from typical right bundle branch block is usually apparent in the lateral precordial leads, because Brugada pattern does not have the widened S-wave due to delayed terminal conduction seen in right bundle branch block. The ECG findings can be variable, with the same patient having type 1, type 2, as well as a normal ECG intermittently. [5] The type 1 ECG pattern is more diagnostic of Brugada syndrome. [3] The diagnosis of Brugada syndrome requires the ECG pattern in at least two right precordial leads (V1-V3) and any of the following: Ventricular fibrillation (VF), polymorphic ventricular tachycardia, inducible ventricular tachycardia during electrophysiology (EP) study, unexplained syncope suggesting tachyarrhythmia, nocturnal agonal respiration, family history of SCD younger than 45 years of age, or family history of type 1 Brugada pattern ECG. [3] The diagnosis is type 1 Brugada syndrome if the ECG pattern is type 1. The diagnosis is type 2 Brugada syndrome if the ECG pattern is type 2 which converts to type 1 with drug challenge using a sodium channel blocker.
GENETICS AND PATHOPHYSIOLOGY OF BRUGADA SYNDROME
The mutations for Brugada syndrome affect the cardiac sodium channel, mainly through the SCN5A genes, which encode the subunits of these channels. [3, 6] The mutation is a loss of function resulting in a reduction of sodium inflow current, thereby reducing phase 0 depolarization of the action potential. The transient outward current (Ito), now opposed by a decreased inward sodium current causes an accentuated "spike and dome" morphology of the phase 1 of the action potential. [7] Most of this alteration in the action potential occurs in the epicardial portion of the myocardium where Ito has higher expression while the action potential in the endocardium remains unchanged. The result is a voltage gradient across the myocardium, with the ECG showing ST-segment elevation.
The impaired sodium channels in epicardial cells may result in localized conduction block. However, the defective sodium channels also cause a shortened plateau phase, phase 2, of the cardiac action potential due to decreased activation of calcium channels, and this results in a shorter action potential duration more so in the epicardial layer. With a shorter phase 2, a shorter refractory period results, and these epicardial cells recover the ability to propagate the action potential sooner. The combination of localized conduction block with the shortened phase 2 in the epicardium creates electrical dispersion predisposing patients to localized re-entry called phase 2 re-entry, which can precipitate ventricular arrhythmias. [8] Other genes may be responsible for the manifestation of the Brugada syndrome suggesting the problem may be an imbalance between inflow and outflow currents during the cardiac action potential. SCN10A mutations also result in a loss of function in a subunit of the sodium channel gene. [9] Mutations in L-type calcium channel ion channels have also been described. [10] However, most patients with Brugada syndrome do not have an identifiable mutation. [3, 11] In addition to the genetic factors, microscopic abnormalities likely contribute to the genesis of arrhythmias as well. Although Brugada syndrome typically is not associated with structural heart disease, there is evidence of microscopic fibrosis and inflammation with resultant conduction delay. [12, 13] The fibrosis and inflammation may cause a delay in the conduction of the action potential as well as heterogeneity in myocardial refractory periods. [14] DIFFERENTIAL DIAGNOSIS OF BRUGADA SYNDROME Conditions that mimic the Brugada ECG pattern should be excluded. These include early repolarization, acute pericarditis, myocardial ischemia, arrhythmogenic right ventricular cardiomyopathy, dissecting aortic aneurysm, and pulmonary embolism. Metabolic disturbances such as hypothermia, hyperkalemia, and hypercalcemia also can result in the typical ECG pattern. Also, conditions that impinge on the epicardium such as mediastinal tumors, pectus excavatum, and pericardial effusion have also been described to result in the Brugada ECG pattern [ Table 1 ]. [3, 15, 16] For patients who have a structurally normal heart but with a history of ventricular tachycardia or SCD, the differential diagnosis includes long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia, right ventricular outflow tract ventricular tachycardia, idiopathic left ventricular tachycardia, idiopathic VF, and commotio cordis.
EPIDEMIOLOGY, RISK FACTORS, AND TRIGGERS OF BRUGADA ELECTROCARDIOGRAM PATTERN
Brugada syndrome is uncommon, with an estimated prevalence of 5 in 10,000 patients, [3] but occurs with greater frequency in Japan, up to 1% in some studies. [17] [18] [19] Approximately 10% of patients with the Brugada ECG pattern will subsequently develop the Brugada syndrome. [20] In patients with idiopathic VF, the prevalence is as high as 24%. [21] There is a male preponderance of the Brugada pattern, being almost 10 times more frequent than in females. [22, 23] The mean age of onset is approximately 40 years. Patients with schizophrenia are also more likely to have Brugada pattern ECG, with approximately 12% showing the ECG findings. [24] Certain conditions and factors worsen the expression of Brugada pattern ECG. Fever is a well-described trigger, with the patients frequently being asymptomatic. With these labile ST patients, the prognosis is good in patients having no events during follow-up. [25] For patients who have Brugada pattern while normothermic and during fever, there is a risk of cardiac arrest. [26] Autonomic tone likely plays a role, as the ventricular tachyarrhythmias occur at night when vagal tone predominates. [27, 28] This parasympathetic effect is also seen during the recovery from exercise. [29] Drugs can trigger the Brugada pattern [ Table 2 ]. [30, 31] with tricyclic antidepressants, lithium, diphenhydramine, alcohol, and cocaine being implicated. [32] Isolated cases of beta-blockers and calcium channel blockers causing Brugada ECG pattern are reported, and may be due to inhibition of L-type calcium channels with resultant shortening of the epicardial action potential dome. [3, 32] Alpha-agonists, insulin, and glucose have also been shown to result in ST elevation. [30, 33] Probably the most potent medications in unmasking Brugada ECG pattern are Vaughan Williams Class I medications. Within this class, flecainide, ajmaline, and procainamide may be used in diagnostic testing to identify at-risk patients with inducible type I pattern ECG. A comprehensive list of culprit medications and those to avoid in Brugada patients can be found at www.BrugadaDrugs.org. [31, 34] SUDDEN CARDIAC DEATH AND BRUGADA SYNDROME
The most worrisome manifestation of Brugada syndrome is SCD. The syndrome is likely the cause in 4% of all SCD and 20% of SCD patients without structural heart disease. [3] Most commonly, the occurrence of ventricular tachyarrhythmias is during sleep. [3, 27, 35] If a patient has a history of SCD, there is an 11-fold risk of the arrhythmic event compared to asymptomatic individuals. A history of unexplained syncope also increases the risk but to a lesser degree. [36] Concomitant disorders appear to be associated with increased risk of SCD in Brugada syndrome as well. Atrial fibrillation manifests in approximately 10-20% of Brugada syndrome patients. [3] Among these patients with atrial fibrillation, there was an almost three-fold higher incidence of syncope and VF. [37] The presence of atrial and ventricular arrhythmias may suggest a more advanced disease process. Of note, not all syncope is equal to SCD. The etiology of syncope in 30% of Brugada syndrome patients is due to neurocardiogenic syncope rather than arrhythmia and carries a benign prognosis. [38] Sleep disordered breathing is more frequently seen in Brugada syndrome as well, and nocturnal agonal respiration may represent cardiac arrhythmias such as ventricular tachycardia or fibrillation. [39] These occurrences are concerning, and when combined with Brugada ECG pattern type 1, the diagnosis of Brugada syndrome is made.
MANAGEMENT OF BRUGADA SYNDROME IN NONOPERATIVE SETTINGS
In patients with the Brugada ECG pattern (type 1 or type 2) and any high-risk feature (unexplained syncope, nocturnal agonal respiration, sustained ventricular tachyarrhythmia, or SCD), an implantable cardioverter-defibrillator (ICD) is indicated. [40] Antiarrhythmic therapy may be considered if patients experience recurrent arrhythmias resulting in appropriate ICD shocks, which occur at a rate of 2.6%/year. [41] Amiodarone generally is better tolerated than quinidine, and these medications should be considered in patients who cannot or refuse to have an ICD implanted. One special situation with Brugada syndrome is ventricular tachycardia storm. In these patients, an isoproterenol infusion in the acute setting is helpful.
For
ST-segment elevation greater than or equal to 2 mm, ventricular premature beats, ventricular arrhythmias, or widening of the QRS more than 30% above baseline. [42] Brugada ECG pattern patients should avoid known triggers and conditions that may further worsen the Brugada pattern, and consideration of ICD should be discussed with these patients. [31, 34, 40] However, these asymptomatic patients with drug-induced Brugada pattern type 1 generally have a good prognosis with low-risk of arrhythmic events. For patients with type 2 Brugada ECG pattern but no high-risk family history, drug challenge is not recommended. For patients with type 1 Brugada ECG pattern under baseline conditions, drug challenge should not be performed as the test does not provide clear prognostic value. [3] The role of invasive EP testing in risk stratification of asymptomatic patients with Brugada ECG pattern also remains debatable. In one study of 547 asymptomatic patients with type 1 ECG pattern, inducible sustained ventricular tachyarrhythmias during EP testing predicted future events. [43] Other large registries, including the France, Italy, Netherlands, Germany Brugada registry and PRogrammed ELectrical stimUlation preDictive valuE registry which were comprised of 369 and 308 asymptomatic patients, however, have shown no predictive value of inducible ventricular tachyarrhythmias on future events. [36, 44] Genetic testing is now readily available, and usually involves gene sequencing for SCN5A. While most of the genetic mutations responsible for Brugada syndrome result from mutations in SCN5A, the yield remains low at 15-30%. [11] Furthermore, the lack of a mutation in SCN5A does not rule out Brugada syndrome. Part of the issue is that other mutations such as SCN10A and calcium channel mutations also are becoming more frequently described and are not part of routine testing for Brugada syndrome. Referral to an electrophysiologist or genetic counselor should be considered prior to any genetic tests being performed.
PREOPERATIVE EVALUATION AND PREPARATION
While there are no prospective studies evaluating the preoperative assessment of patients with Brugada ECG or Brugada syndrome, the following recommendations are based on current understanding of the pathophysiology of Brugada syndrome and anesthetic agents. The majority of Brugada patients have an unremarkable perioperative course, but the goal of preoperative evaluation remains to reduce the potential risk of ventricular arrhythmias. An algorithm is suggested in Figure 2 .
If the characteristic Brugada pattern ECG is found during the preoperative evaluation, EP consultation and evaluation should be obtained. [45] The main concern with Brugada syndrome patients is the susceptibility to ventricular tachyarrhythmias and SCD, and this risk is present even with asymptomatic patients. [3, 46] A number of medications are implicated in Brugada pattern ECG, and the patient history should be reviewed for use of these [ Table 2 ]. An up-to-date list can be found at the website, www.BrugadaDrugs.org. [31, 34] Certain medications to be avoided in Brugada patients include Class IA and Class IC antiarrhythmics, tricyclic antidepressive medications, lithium, oxcarbazepine, acetylcholine, and ergonovine. Patients should also be screened for recreational drugs such as cocaine, cannabis, and heavy alcohol use. In patients with known or suspected Brugada syndrome, an electrolyte panel should be checked preoperatively, as hyperkalemia and hypercalcemia can result in the Brugada ECG pattern. [15, 16] Patients who have had an ICD implanted for Brugada syndrome should be programmed with the tachyarrhythmia therapy of the device disabled. [45] Brugada syndrome patients with and without an ICD should have external defibrillator pads placed with an external defibrillator readily available. [47] [48] [49] For patients who require pacing, the ICD (or pacemaker if the patient had a device implanted for bradyarrhythmia therapy only), should be reprogrammed to a nontracking or nonsensing mode such as VOO or DOO depending on the presence of a single or dual chamber device respectively. [45, 47] This programming change is to prevent the device from detecting electrical interference from electrocautery or other electronic equipment in the operating room. Such interference may result in an inappropriate shock by an ICD and inhibition of pacing by the pacemaker function. [47] 
MONITORING AND INTRAOPERATIVE CONSIDERATIONS
Perioperative monitoring in patients with Brugada syndrome depends on the site and complexity of the planned surgery. Multi-lead ECG monitoring should be utilized, preferably with ST trend analysis. [45, [49] [50] [51] The ability to monitor worsening ST-segment elevation may prevent hemodynamically significant arrhythmias by allowing for timely corrective treatment. [45] While there has not been a definitive correlation between ST-segment elevation and resultant ventricular arrhythmias, prior studies suggest a mechanistic link. [28, 33, 52] A temperature probe should also be placed, as the fever has been shown to trigger arrhythmias in Brugada patients. [25, 26, 47, 53] Appropriate warming or cooling should be applied as necessary to maintain normothermia. For major surgery requiring general anesthesia, invasive blood pressure monitoring and central venous access may be helpful. Autonomic tone can change intraoperatively, and increased vagal tone can result in ventricular arrhythmias. [27, 28] Bradycardia, which may be a manifestation of this increased vagal tone, may be seen with the development of the Brugada ECG pattern. [45, 54] A sudden rise in vagal activity immediately before the development of VF has been described in Brugada patients. [52] The intraoperative period is notable for multiple stressors, both leading to sympathetic activity (surgical incision, endotracheal intubation, anesthetic induction, and emergence) as well as sudden increases in parasympathetic tone (tracheal suctioning, peritoneal insufflation, and bowel retraction). The use of atropine and ephedrine has been advocated to reduce vagal tone in a series of patients undergoing general anesthesia for ICD insertion. [51] If the Brugada ECG pattern becomes more prominent with ST elevation, isoproterenol can be used to restore ST segments to the pretreatment level. [51, 55, 56] ST elevation in these patients can also be due to selective alpha-adrenergic receptor stimulation, seen with methoxamine alone or with norepinephrine in combination with propranolol. Alpha-adrenergic blockade in some patients has been shown to reduce this ST elevation in some patients. [33] PERIOPERATIVE PHARMACOLOGY Antiemetics Droperidol and 5-HT 3 receptor antagonists are not contraindicated as antiemetics in Brugada syndrome, but it should be noted that there is a potential association between long QT and Brugada syndrome. Metoclopramide and dimenhydrinate are preferably avoided. Phenothiazines are also to be avoided. [31, 34, 57] Opioids and analgesics Fentanyl use has been described in multiple case reports and series without incident. [47] [48] [49] [50] [51] [58] [59] [60] [61] [62] There is limited data on the use of remifentanil; [63] due to its ultra-short duration of action it may be of use in short procedures. Fentanyl, meperidine, and ketorolac have been successfully used for postoperative analgesia in patients with Brugada syndrome. [49, 50, 59] Ketamine has been used for sedation in combination with midazolam. [62] OTHER MEDICATIONS Pharmacological interactions during anesthesia and autonomic imbalance may facilitate ECG changes in Brugada syndrome. These ECG changes are usually resolved when the triggering drugs are discontinued. [47] Cholinergic drugs, such as neostigmine, can increase ST elevation. [55] Beta-adrenergic antagonists and alpha-adrenergic agonists may also exacerbate ST elevation. [33] As such, typical recommendations for beta-blockade to be used perioperatively may not be applicable in Brugada patients. [47] Conversely, beta-adrenergic agonists or alpha-adrenergic antagonists should be considered if ST-changes appear in the absence of arrhythmias due to the possible link between ST-segment elevation and associated ventricular arrhythmias. [33, 47] Isoproterenol is the beta-adrenergic agonist of choice and has been reported to restore elevated ST segments to the pretreatment level in patients undergoing a challenge test with pilsicainide. [51] Atropine and ephedrine have been used for the treatment of bradycardia and hypotension, respectively, without complications. [51] Although specific data are lacking, alpha-2 adrenergic agonists, such as clonidine and dexmedetomidine, may produce sympathetic suppression and increased vagal stimulation of the heart. [64] Other drugs such as Class IA and Class IC antiarrhythmics (disopyramide, procainamide, flecainide, and ajmaline) have a direct drug effect that may worsen ST-segment elevation. [33, 47, 49] Ajmaline administration, even while isoproterenol was infusing, has resulted in ventricular tachycardia and VF with cardiac arrest. [62] In contrast, Class IB antiarrhythmic drugs (mexiletine and lidocaine) likely have no effect on ST-segment elevation. [33, 55] 
LOCAL ANESTHETICS
The sodium channel blocking the action of local anesthetics may exacerbate Brugada ECG changes. However, neuraxial techniques have also been used in patients with Brugada syndrome. [33, 59, 60] Bupivacaine epidurally has been implicated in the evolution of a Brugada-type ECG possibly due to its longer duration of action. [47, 59, 65] It has been recommended to avoid bupivacaine in these patients, because of its effect on the rapid phase of depolarization, and because it remains bound to sodium channels longer than other local anesthetics. [34] Other authors have reported the use of bupivacaine for epidural and intrathecal anesthesia without adverse effects. [48] The total dose of bupivacaine may need to be reduced in Brugada patients if shorter-acting alternatives such as lidocaine cannot be used. [47] [48] [49] The use of lidocaine has also been described to cause ST-segment elevation on its own. [47, 66] However, the ST elevation may be due to concurrent administration of medications such as propofol along with the lidocaine. [66] Also, intravenous administration of lidocaine has been used uneventfully to attenuate intubation-related hemodynamic changes. [51] Because of this, the use of lidocaine is preferable in these patients. For Brugada patients undergoing implantation of an ICD, local anesthesia with lidocaine or bupivacaine is adequate for placement of most ICDs. [47] Additional sedation is required for defibrillation function testing and for subpectoral implants. [47] [48] [49] These situations may require general endotracheal anesthesia with the use of volatile anesthetics.
VOLATILE ANESTHETICS
The use of volatile agents in Brugada patients has no documented issues, but part of the concern comes from prolonged QT syndromes and use of volatile agents that may further prolong the QT interval. [47, 67] Most genetically proven Brugada syndrome patients have a mutation in SCN5A, and this gene has also been linked to prolonged QT syndrome. [47] Isoflurane has been shown to prolong the QT interval while halothane has been shown to shorten the QT interval. [47] Sevoflurane has not been shown to have a significant effect on the QT interval. While both isoflurane [48, 66, 68] and sevoflurane [47, 66, 67] have been used successfully in these patients, sevoflurane likely should be considered the preferred volatile agent in Brugada patients.
NITROUS OXIDE
There is no laboratory data to question the use of nitrous oxide in Brugada patients. Multiple clinical reports have described its uneventful use in combination with propofol or a volatile agent in these patients. [47, 51, 55, 58, 62, 68, 69] 
INTRAVENOUS AGENTS
The use of propofol in patients with Brugada syndrome is somewhat controversial. [31, 34, 70] There are several case reports that detail a Brugada-type ECG pattern in association with long-term propofol abuse and propofol infusion syndrome; however, none of these patients was shown to have Brugada syndrome. [45, 59, 66, 70] There are numerous case reports and series in which propofol has been used without incident in these patients. [47, 50, 51, 55, [58] [59] [60] [61] 63, 66, 69] In one cohort of patients undergoing ICD implantation, propofol was used for induction of anesthesia, and no patients developed any malignant arrhythmias. [70] One patient received propofol to maintain anesthesia and had an unremarkable perioperative course. While there are theoretical concerns about the use of propofol in Brugada syndrome patients, there have been no documented arrhythmias, but ST-segment elevation has been described. [66] Thiopental [48, 49, 62] and midazolam [51, 58, 59] have also been used uneventfully in Brugada patients. Self-limited ST-segment elevations were described in one patient after etomidate use. [66] NEUROMUSCULAR BLOCKERS AND REVERSAL AGENTS Succinylcholine, [48, 58] vecuronium, [48, 49, 51, 68] atracurium, [58] cisatracurium, [50] and mivacurium [51] have all been used without adverse effects. Parasympathetic stimulation specifically by neostigmine has been reported to increase ST changes in Brugada patients. [33, 48, 56, 71] In another report, the administration of neostigmine coincided with the development of pulmonary edema. [47] There are concerns about the use of neostigmine for reversal of neuromuscular block because of the possibility of triggering the characteristic ECG pattern. [48, 50, 51, 68] However, multiple case reports have documented neostigmine usage combined with atropine [58, 68] or glycopyrrolate [47, 48, 55, 66] without complications.
POSTOPERATIVE CARE
After surgery, patients with a pacemaker or ICD should have the settings restored to its preoperative mode. [45] Brugada patients may have more susceptibility to arrhythmias such as from phase 2 block, so the time spent in nontracking modes (VOO or DOO) should be minimized. [47] Due to the risk of postoperative arrhythmias, continuous ECG monitoring should continue for up to 36 h postoperatively. [45, 47, 49, 50, 54, 55, 68, 72] Sinus tachycardia and isolated premature ventricular complexes can be seen without increasing the occurrence of other more worrisome arrhythmias. [66] CONCLUSIONS Brugada syndrome and Brugada ECG pattern are uncommon but carry the risk of ventricular arrhythmias and even SCD. With certain triggers, including drug exposure, this condition may pose a significant risk to the patient. The perioperative period may have fluctuations in autonomic tone, and potential exposures to triggers for patients with Brugada syndrome or the ECG pattern. While most Brugada syndrome and Brugada ECG pattern patients have unremarkable perioperative courses, these patients will benefit from expert consultation and meticulous management of triggers and conditions thereby reducing potential morbidity and mortality.
